While untreated and short-term PLX5622-treated WT and GFAP-IL6 mice had a median clinical score of zero during the course of the experiment, both untreated and short-term PLX5622-treated GFAP-IFN mice showed signs of mild ataxia beginning at six weeks (Figure 8C). This evidence concerns the gene GFAP and cerebellar ataxia.